ArticleBMC cancer2025
NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- mBiology direct · 2026Review
- NSUN5 and RNA mFrontiers in cell and developmental biology · 2026Review
- Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications.Biological procedures online · 2025Review
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAerobic glycolysis is a hallmark of cancers including liver hepatocellular carcinoma (LIHC). RNA m5C methylation is involved in LIHC progression. However, the effect of a m5C writer, NSUN5, on glycolysis in LIHC remains not known. The present study aimed to investigate the effect of NSUN5 on glycolysis in LIHC and the molecular mechanism.
methodsNSUN5 and EFNA3 expression data were acquired from The Cancer Genome Atlas database. Cell viability and glycolysis were evaluated. Tumor growth was evaluated using the xenograft tumor model. The effect of NSUN5 on EFNA3 m5C methylation was evaluated using methylated RNA immunoprecipitation and dual-luciferase reporter assay.
resultsWe found that NSUN5 and EFNA3 expression was increased in LIHC and related to poor survival. Knocking down NSUN5 inhibited LIHC cell viability and glycolysis in vitro, and inhibited tumor growth and glycolysis in vivo. Moreover, the expression of NSUN5 was positively correlated with that of EFNA3. NSUN5 stabilized EFNA3 by promoting m5C modification of EFNA3. Additionally, overexpression of EFNA3 reversed the inhibition of cell viability and glycolysis induced by NSUN5 silence.
conclusionSilencing of NSUN5 decelerates LIHC progression by inhibiting glycolysis mediated by EFNA3 with m5C modification, highlighting the potential of NSUN5 as a therapeutic target for LIHC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.